Chengdu Olymvax Biopharmaceuticals (SH:688319) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-01-27 23:37Core Viewpoint - The major shareholder, Taichang Group, plans to reduce its stake in Chengdu Olin Biotechnology Co., Ltd. due to personal funding needs, with a maximum reduction of 6,000,000 shares, representing up to 1.4789% of the company's total share capital [3][10]. Shareholder Holding Situation - As of the report date, Taichang Group holds 25,893,040 shares, accounting for 6.38% of the total share capital of Olin Biotechnology [2]. Reduction Plan Details - Taichang Group intends to reduce its holdings through centralized bidding or block trading within three months after the announcement, starting 15 trading days post-announcement [3][6]. - The reduction price will be determined based on market conditions at the time of the sale [3]. - If any changes occur in the company's share structure during the reduction period, the planned reduction quantity and ratio will be adjusted accordingly [3]. Commitment and Compliance - Taichang Group has committed not to transfer or manage its pre-IPO shares for 12 months following the company's stock listing [6][7]. - The group will adhere to relevant laws and regulations regarding share reduction, including limits on the number of shares that can be sold within specified periods [7][8]. Historical Context - Taichang Group has not reduced its shareholding since the company went public [5].